Amgen’s Statin Intolerance Study May Not Cure What Ails PCSK9 Inhibitors
This article was originally published in The Pink Sheet Daily
Executive Summary
GAUSS-3 study shows role for Repatha as an alternative for patients with high cholesterol who can’t take statins, but real world impact may be minimal, due to pushback from payers – and even physicians.
You may also be interested in...
PCSK9 Inhibitors' First Birthday Brings Sluggish Sales And More Bad Press
Analysis published in the Journal of the American Medical Association is the latest to argue that PCSK9 inhibitors are not cost-effective.
PCSK9 Inhibitors May Feel Effects Of FDA Judgment On IMPROVE-IT
Agency's decision on cardiovascular risk reduction claims for Merck's Zetia and Vytorin may serve as a regulatory barometer for the magnitude and robustness of effect that will be expected in outcomes studies for other LDL-C-lowering agents.
Rare Disease Roundtable: Dealing With Pricing Pressure
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.